Literature DB >> 8839647

Colonization and infection with Moraxella catarrhalis in childhood.

R Berner1, R F Schumacher, M Brandis, J Forster.   

Abstract

In a prospective clinical study, rates of isolation of Moraxella catarrhalis in nasopharyngeal aspirates from 122 children with respiratory tract infection and 72 healthy controls were compared. In the patient group, Moraxella catarrhalis and Streptococcus pneumoniae were the most frequently isolated pathogens (38% and 42%, respectively). Monocultures of each pathogen were equally distributed in patients and controls (41% and 42%), whereas mixed infections were found more frequently in the patient group (42% vs 14%; normal flora, 17% vs 44%). Moraxella catarrhalis appears to be a relevant respiratory pathogen. The isolation of two or more pathogens in nasopharyngeal aspirates seems to be as indicative of relevant infection as is monoculture.

Entities:  

Mesh:

Year:  1996        PMID: 8839647     DOI: 10.1007/bf01691320

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

Review 1.  Branhamella catarrhalis: an organism gaining respect as a pathogen.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

2.  Comparison of the nasal bacterial floras in two groups of healthy subjects and in patients with acute maxillary sinusitis.

Authors:  H R Jousimies-Somer; S Savolainen; J S Ylikoski
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

3.  Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood.

Authors:  D Goldblatt; M W Turner; R J Levinsky
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

4.  Beta-lactamase production in the upper respiratory tract flora in relation to antibiotic consumption: a study in children attending day nurseries.

Authors:  S Mölstad; I Eliasson; B Hovelius; C Kamme; C Schalén
Journal:  Scand J Infect Dis       Date:  1988

5.  Interaction between Streptococcus pneumoniae and Branhamella catarrhalis obtained from double-colonized, healthy nasopharynx and double-infected, diseased middle ear cavity.

Authors:  L E Stenfors; S Räisänen
Journal:  Scand J Infect Dis       Date:  1989

6.  Erythromycin treatment is beneficial for longstanding Moraxella catarrhalis associated cough in children.

Authors:  J Darelid; S Löfgren; B E Malmvall
Journal:  Scand J Infect Dis       Date:  1993

7.  Children with persistent cough--outcome with treatment and role of Moraxella catarrhalis?

Authors:  P Gottfarb; A Brauner
Journal:  Scand J Infect Dis       Date:  1994

8.  Diagnosis of respiratory syncytial virus infection in children: comparison of viral antigen detection and serology.

Authors:  O Meurman; H Sarkkinen; O Ruuskanen; P Hänninen; P Halonen
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

9.  Role of Moraxella (Branhamella) catarrhalis as a respiratory pathogen in children.

Authors:  M Korppi; M L Katila; J Jääskeläinen; M Leinonen
Journal:  Acta Paediatr       Date:  1992-12       Impact factor: 2.299

10.  Disk diffusion susceptibility testing of Branhamella catarrhalis with ampicillin and seven other antimicrobial agents.

Authors:  G V Doern; T Tubert
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

View more
  10 in total

Review 1.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells.

Authors:  Rachel Balder; Thomas M Krunkosky; Chi Q Nguyen; Lacey Feezel; Eric R Lafontaine
Journal:  Infect Immun       Date:  2009-08-10       Impact factor: 3.441

3.  Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.

Authors:  Dai-Fang Liu; John C McMichael; Steven M Baker
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

4.  Expression of type IV pili by Moraxella catarrhalis is essential for natural competence and is affected by iron limitation.

Authors:  Nicole R Luke; Amy J Howlett; Jianqiang Shao; Anthony A Campagnari
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Moraxella tetraodonis sp. nov., isolated from freshwater pufferfish (Tetraodon cutcutia) skin.

Authors:  Lipika Das; Subrata K Das
Journal:  Arch Microbiol       Date:  2022-06-14       Impact factor: 2.552

Review 6.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

7.  The Hag protein of Moraxella catarrhalis strain O35E is associated with adherence to human lung and middle ear cells.

Authors:  Melissa M Holm; Serena L Vanlerberg; Darren D Sledjeski; Eric R Lafontaine
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Salivary antibodies directed against outer membrane proteins of Moraxella catarrhalis in healthy adults.

Authors:  Patricia Stutzmann Meier; Nadja Heiniger; Rolf Troller; Christoph Aebi
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells.

Authors:  Melissa M Holm; Serena L Vanlerberg; Ian M Foley; Darren D Sledjeski; Eric R Lafontaine
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Authors:  Teresa L Shaffer; Rachel Balder; Sean W Buskirk; Robert J Hogan; Eric R Lafontaine
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.